Sarepta Therapeutics, Inc.
215 First Street
Cambridge, MA -2142
United States
839 articles about Sarepta Therapeutics, Inc.
-
AVI BioPharma, Inc. Successful Ebola Study Results Highlighted In Nature Reviews Drug Discovery
3/7/2006
-
AVI BioPharma, Inc. Announces Hepatitis C Virus License Agreement With Chiron Corporation
1/27/2006
-
AVI BioPharma, Inc. Says Influenza Drug Effective In Trials; Shares Rise
1/20/2006
-
AVI BioPharma, Inc.'s NEUGENE Shows Success Against Deadly Ebola Virus; Results Published In Online Journal Public Library Of Science (PLoS) Pathogens
1/13/2006
-
AVI BioPharma, Inc. Reports Favorable Safety And Pharmacokinetic Data From Its Clinical Trial Targeting Hepatitis C Virus
1/10/2006
-
Increased Defense-Related Funding Of AVI BioPharma Approved; $11 Million Allocated For Development Of Therapeutics For Ebola, Marburg And Dengue Viruses, And For Countermeasures For Anthrax And Ricin Toxins
1/4/2006
-
AVI BioPharma, Inc. Announces $22.6 Million Direct Equity Placement
11/15/2005
-
AVI BioPharma, Inc. Reports Third Quarter Financial Results
11/4/2005
-
Results From AVI BioPharma, Inc.'s Antiviral Program Published In Two Virology Journals
10/25/2005
-
AVI BioPharma, Inc. Provides Update On Influenza Drug Development Program
10/20/2005
-
AVI BioPharma, Inc. Releases Good Neugene Animal Data
10/14/2005
-
AVI BioPharma Included In Initial Defense Funding Allocation
10/3/2005
-
AVI BioPharma, Inc. To Testify Before Congressional Committee On Bioterrorism Research And Development
6/9/2005
-
AVI BioPharma, Inc. (AVII) Announces Positive Results In NEUGENE Antisense Studies With Collaborators Targeting Emerging Viral Diseases
4/12/2005
-
Biotech Versus Bioterror
2/14/2005
-
AVI BioPharma And USAMRIID Announce NEUGENE Antisense Drug Demonstrates Efficacy Against Ebola Virus
11/1/2004
-
AVI BioPharmaTo Testify Before Congressional Committee On Legislative Proposal For BioShield II
10/6/2004
-
AVI BioPharma Announces NEUGENE Antisense Collaboration With USAMRIID On Biodefense Agents
8/10/2004
-
West Nile Drug Makers To End Research Due To Financial And Logistical Concerns
4/7/2004